Stocks › NKTR

NEKTAR THERAPEUTICS

NKTR·Nasdaq·United States United States·USD
$30.20
-2.34 (-7.19%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
NKTR
NEKTAR THERAPEUTICS · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
NKTRS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of NKTR by members of U.S. Congress · 4 on record
All congressional trades →
PoliticianStockTypeFiledTraded
Josh GottheimerJosh GottheimerHouse · D · NJ NKTRNEKTAR THERAPEUTICS · Stock Sale
$1,001 - $15,000
Oct 2, 2018 Jun 21, 2018 Filing ↗
Josh GottheimerJosh GottheimerHouse · D · NJ NKTRNEKTAR THERAPEUTICS · Stock Purchase
$1,001 - $15,000
Oct 2, 2018 Jun 6, 2018 Filing ↗
Eric SwalwellEric SwalwellHouse · D · CA NKTRNEKTAR THERAPEUTICS · Stock Sale
$1,001 - $15,000
Apr 7, 2015 Apr 1, 2015 Filing ↗
Eric SwalwellEric SwalwellHouse · D · CA NKTRNEKTAR THERAPEUTICS · Stock Sale
$1,001 - $15,000
Feb 27, 2015 Jan 31, 2015 Filing ↗

Whale Activity

Position changes in NKTR reported for 2026-09-30 by 280 institutional filers
Increased: 88New: 34Held: 38Decreased: 68Closed: 38No prior filing: 14
  • Increased88
  • New34
  • Held38
  • Decreased68
  • Closed38
  • No prior filing14
FilerSharesValueChange
FMR LLC5.1M$310.1Mincreased
Two Seas Capital LP3.3M$202.6Mincreased
BlackRock, Inc.2.9M$173.9Mdecreased
BVF INC/IL2.1M$129.2Mdecreased
STATE STREET CORP1.8M$107.3Mincreased
VANGUARD CAPITAL MANAGEMENT LLC1.5M$90.9Mincreased
TWO SIGMA INVESTMENTS, LP1.2M$73.2Mincreased
GEODE CAPITAL MANAGEMENT, LLC891.9K$54.0Mincreased
MORGAN STANLEY830.2K$50.3Mdecreased
Prosight Management, LP785.0K$47.5Mdecreased
ARMISTICE CAPITAL, LLC700.0K$42.4Mdecreased
GOLDMAN SACHS GROUP INC621.2K$37.6Mincreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by NKTR insiders, by quarter · Form 4
-50.0K-25.0K025.0K50.0K2025 Q1: -45.1K2025 Q12025 Q2: -43.9K2025 Q22025 Q3: -25.2K2025 Q32025 Q4: 02025 Q42026 Q1: -4,4702026 Q12026 Q2: -31.9K2026 Q22026 Q3: -6042026 Q32026 Q4: -6212026 Q4

Recent Insider Transactions

966 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
ROBIN HOWARD WPresident & CEO · Director Sale −429 $35.85 $15K Nov 17, 2026 Form 4 ↗
Zalevsky JonathanChief R&D Officer Sale −192 $35.85 $7K Nov 17, 2026 Form 4 ↗
WHITFIELD ROY ADirector Grant / award +2,000 $0.00 $0 Sep 23, 2026 Form 4 ↗
GREER R SCOTTDirector Grant / award +2,000 $0.00 $0 Sep 23, 2026 Form 4 ↗
CHESS ROBERTDirector Grant / award +2,000 $0.00 $0 Sep 23, 2026 Form 4 ↗
Brainard DianaDirector Grant / award +2,000 $0.00 $0 Sep 23, 2026 Form 4 ↗
Ajer Jeffrey RobertDirector Grant / award +2,000 $0.00 $0 Sep 23, 2026 Form 4 ↗
Zalevsky JonathanChief R&D Officer Sale −186 $71.98 $13K Aug 18, 2026 Form 4 ↗
ROBIN HOWARD WPresident & CEO · Director Sale −418 $71.98 $30K Aug 18, 2026 Form 4 ↗
Zalevsky JonathanChief R&D Officer Sale −5,681 $70.00 $398K Jun 30, 2026 Form 4 ↗
ROBIN HOWARD WPresident & CEO · Director Sale −4,500 $61.65 $277K Jun 17, 2026 Form 4 ↗
ROBIN HOWARD WPresident & CEO · Director Sale −5,500 $60.81 $334K Jun 17, 2026 Form 4 ↗
ROBIN HOWARD WPresident & CEO · Director Sale −4,697 $60.71 $285K Jun 16, 2026 Form 4 ↗
ROBIN HOWARD WPresident & CEO · Director Sale −5,303 $59.97 $318K Jun 16, 2026 Form 4 ↗
Zalevsky JonathanChief R&D Officer Sale −5,538 $60.71 $336K Jun 15, 2026 Form 4 ↗
Zalevsky JonathanChief R&D Officer Sale −199 $65.51 $13K May 19, 2026 Form 4 ↗
ROBIN HOWARD WPresident & CEO · Director Sale −444 $65.51 $29K May 19, 2026 Form 4 ↗
Zalevsky JonathanChief R&D Officer Sale −180 $73.00 $13K Feb 18, 2026 Form 4 ↗
ROBIN HOWARD WPresident & CEO · Director Sale −423 $73.00 $31K Feb 18, 2026 Form 4 ↗
Zalevsky JonathanChief R&D Officer Sale −3,867 $35.67 $138K Jan 20, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding NKTR · SEC Form N-PORT
FundSharesValue% of fundAs of
Fidelity Growth Company Fund
Fidelity Mt. Vernon Street Trust
1.9M$132.1M0.14%Aug 31, 2026
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
1.1M$75.1M0.00%Jun 30, 2026
iShares Russell 2000 ETF
iShares Trust
896.1K$62.6M0.08%Jun 30, 2026
Fidelity Growth Company K6 Fund
Fidelity Mt. Vernon Street Trust
500.4K$35.7M0.13%Aug 31, 2026
Fidelity Series Growth Company Fund
Fidelity Mt. Vernon Street Trust
424.6K$30.3M0.12%Aug 31, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
387.6K$27.1M0.03%Jun 30, 2026
Fidelity Small Cap Index Fund
Fidelity Salem Street Trust
376.9K$26.6M0.08%Jul 31, 2026
LORD ABBETT DEVELOPING GROWTH FUND INC
LORD ABBETT DEVELOPING GROWTH FUND, INC.
273.9K$23.3M1.05%Apr 30, 2026
iShares Russell 2000 Growth ETF
iShares Trust
285.3K$19.9M0.13%Jun 30, 2026
VANGUARD RUSSELL 2000 INDEX FUND
VANGUARD SCOTTSDALE FUNDS
197.5K$14.1M0.08%Aug 31, 2026

Mutual funds and ETFs whose N-PORT filings list NKTR's shares (CUSIP 640268306), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 1.8M shares5.2%
    Nov 10, 2026 · ↗
  • Sina ToussiSCHEDULE 13G/A · passive (13G) · 3.3M shares9.8%
    Sep 28, 2026 · ↗
  • Two Seas Capital GP LLCSCHEDULE 13G/A · passive (13G) · 3.3M shares9.8%
    Sep 28, 2026 · ↗
  • Two Seas Capital LPSCHEDULE 13G/A · passive (13G) · 3.3M shares9.8%
    Sep 28, 2026 · ↗
  • Sina ToussiSCHEDULE 13G/A · passive (13G) · 3.1M shares9.1%
    Aug 14, 2026 · ↗
  • Two Seas Capital GP LLCSCHEDULE 13G/A · passive (13G) · 3.1M shares9.1%
    Aug 14, 2026 · ↗
  • Two Seas Capital LPSCHEDULE 13G/A · passive (13G) · 3.1M shares9.1%
    Aug 14, 2026 · ↗
  • BVF INC/ILSCHEDULE 13G/A · passive (13G) · 2.4M shares7.1%
    Aug 14, 2026 · ↗
  • BVF PARTNERS L P/ILSCHEDULE 13G/A · passive (13G) · 2.4M shares7.1%
    Aug 14, 2026 · ↗
  • BVF GP HOLDINGS LLCSCHEDULE 13G/A · passive (13G) · 2.2M shares6.5%
    Aug 14, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming nektar therapeutics as client

No lobbying filings found naming NEKTAR THERAPEUTICS as the client.

  • BGR GOVERNMENT AFFAIRSNEKTAR THERAPEUTICS · 2022 Q2 · HCR—
    Filing ↗
  • BGR GOVERNMENT AFFAIRSNEKTAR THERAPEUTICS · 2022 Q1 · HCR$50K
    Filing ↗
  • BGR GOVERNMENT AFFAIRSNEKTAR THERAPEUTICS · 2021 Q4 · HCR$50K
    Filing ↗
  • BGR GOVERNMENT AFFAIRSNEKTAR THERAPEUTICS · 2021 Q3 · HCR$50K
    Filing ↗
  • BGR GOVERNMENT AFFAIRSNEKTAR THERAPEUTICS · 2021 Q2 · HCR$50K
    Filing ↗

Government Contracts

Federal awards to NEKTAR THERAPEUTICS · USAspending

No federal contract awards found for NEKTAR THERAPEUTICS.

U.S. Patents

Recent USPTO applications naming NEKTAR THERAPEUTICS

No USPTO patent applications found for NEKTAR THERAPEUTICS.

Annual Financials

From NKTR's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$55.2M$98.4M$90.1M$92.1M$101.9M
Operating income-$140.1M-$105.2M-$263.7M-$376.2M-$446.1M
Net income-$164.1M-$119.0M-$276.1M-$368.2M-$523.8M
Diluted EPS-$9.73-$8.68-$1.45-$1.97-$2.86
Operating cash flow-$208.5M-$175.7M-$192.6M-$304.0M-$412.7M
Cash and equivalents$15.1M$44.3M$35.3M$88.2M$25.2M
Total assets$280.4M$303.9M$398.0M$710.6M$1.12B
Total liabilities$190.6M$243.1M$267.0M$344.0M$437.7M
Shareholders' equity$89.8M$60.7M$131.0M$366.6M$679.5M

As NEKTAR THERAPEUTICS tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Mar 13, 2026 ↗

Stock Splits

Every split and reverse split in the price history
  • 1-for-15Reverse splitJun 9, 2025
  • 2-for-1Stock splitAug 23, 2000

Split dates and ratios from the price history · Close Prices from Tiingo.com

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 7.01Reg FD disclosureNov 13, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsNov 12, 2026
    EDGAR ↗
  • 8-K · Items 7.01, 9.01Reg FD disclosureOct 1, 2026
    EDGAR ↗
  • 8-K · Items 8.01Other eventsSep 25, 2026
    EDGAR ↗
  • 8-K · Items 7.01, 9.01Reg FD disclosureSep 8, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsAug 13, 2026
    EDGAR ↗
  • 8-K · Items 5.07Shareholder voteJun 5, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 5.02, 9.01Material agreement · Officer / director changeMay 8, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsMay 7, 2026
    EDGAR ↗

About NEKTAR THERAPEUTICS

From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersSAN FRANCISCO, CA
IncorporatedDE
Former namesINHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS